

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 13, 2023 February 5, 2024

Sodium-Glucose Co-Transporter (SGLT-2) Inhibitor Agents

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors	
PREFERRED	Farxiga [®] (dapagliflozin); Invokana [®] (canagliflozin); Jardiance [®] (empagliflozin)
NON-PREFERRED	Steglatro [®] (ertugliflozin)
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitor/Biguanide Combination Products	
PREFERRED	Invokamet [®] (canagliflozin/metformin); Synjardy [®] (empagliflozin/metformin); Xigduo XR [®] (dapagliflozin/metformin)
NON-PREFERRED	Invokamet XR [®] (canagliflozin/metformin); Segluromet [®] (ertugliflozin/metformin); Synjardy XR [®] (empagliflozin/metformin)
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitor/Dipeptidyl Peptidase 4 (DPP-4) Inhibitor Combination Products	
PREFERRED	Glyxambi [®] (empagliflozin/linagliptin)
NON-PREFERRED	Qtern [®] (dapagliflozin/saxagliptin); Steglujan [®] (ertugliflozin/sitagliptin)
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitor /Dipeptidyl Peptidase 4 (DPP-4) Inhibitor/Biguanide Combination Product	
PREFERRED	Trijardy XR[®] (empagliflozin/linagliptin/metformin)
NON-PREFERRED	

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a documented diagnosis of Type 2 diabetes mellitus.
- Patient must have both of the following (*official labs required*):
 - HgbA1C ≥ 7.0%, **AND**
 - eGFR based on the prescribing information.
- Patient must have documented trial and failure of the preferred agents in the respective requested SGLT-2 inhibitor class.
- The medication requested will not be used concomitantly with another SGLT-2 inhibitor.

Note: These medications are not indicated to be used exclusively for weight loss.

CONTINUATION OF THERAPY

- Patient met initial review criteria.
- Documentation of improved clinical response.
- Dosing is appropriate as per labeling or is supported by compendia.

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 13, 2023 February 5, 2024

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>